Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Literature
  1. Rasmussen BK, Olesen J: Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992, 12: 221-228. 10.1046/j.1468-2982.1992.1204221.x.View ArticlePubMed
  2. Headache Classification Committee of the International Headache Society: The international classification of headache disorders: 3th edition (beta version). Cephalalgia. 2013, 33: 629-808.View Article
Metadata
Title
P050. Migrainous aura: when to worry?
Authors
Matteo Fuccaro
Lucia Nardetto
Giorgio Zanchin
Federico Mainardi
Ferdinando Maggioni
Publication date
01-12-2015
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue Special Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-16-S1-A85

Other articles of this Special Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue

Poster presentation

P032. Coenzyme Q-10 and migraine: a lovable relationship. The experience of a tertiary headache center

Poster presentation

P065. Cluster headache: when to worry?

Poster presentation

P033. Headache and commuting: preliminary data in a group of workers

Invited speaker presentation

The costs of headache disorders

Poster presentation

P052. Patient's subjective judgement on the ease of use, speed of onset of action, efficacy and tolerability of Diclofenac sodium HPβCD (25 mg/mL) solution for subcutaneous injection vs Diclofenac potassium 50 mg for oral solution for the acute treatment of migraine

Oral presentation

O011. Patients with “prolonged aura” do not show clinical or demographic differences from the patients with “typical aura”